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The molecular chaperone Hsp90 protects deregu-
lated signaling proteins that are vital for tumor
growth and survival. Tumors generally display sensi-
tivity and selectivity toward Hsp90 inhibitors;
however, the molecular mechanism underlying this
phenotype remains undefined. We report that the
mitotic checkpoint kinase Mps1 phosphorylates a
conserved threonine residue in the amino-domain
of Hsp90. This, in turn, regulates chaperone function
by reducing Hsp90 ATPase activity while fostering
Hsp90 association with kinase clients, including
Mps1. Phosphorylation of Hsp90 is also essential
for the mitotic checkpoint because it confers Mps1
stability and activity. We identified Cdc14 as the
phosphatase that dephosphorylates Hsp90 and dis-
rupts its interaction with Mps1. This causes Mps1
degradation, thus providing a mechanism for its
inactivation. Finally, Hsp90 phosphorylation sensi-
tizes cells to its inhibitors, and elevated Mps1 levels
confer renal cell carcinoma selectivity to Hsp90
drugs. Mps1 expression level can potentially serve
as a predictive indicator of tumor response to
Hsp90 inhibitors.872 Cell Reports 14, 872–884, February 2, 2016 ª2016 The AuthorsINTRODUCTION
Heat shock protein-90 (Hsp90) is an essential molecular chap-
erone in eukaryotes, and it is involved in the maturation, protec-
tion, and activation of a group of proteins referred to as ‘‘clients,’’
(see the website maintained by D. Picard; https://www.picard.
ch/downloads/Hsp90interactors.pdf) (Picard, 2002; Ro¨hl et al.,
2013; Taipale et al., 2010). Hsp90 clients are enriched in
signal transducers, including protein kinases and transcription
factors. Hsp90 and a distinct set of co-chaperone proteins
such as Cdc37 ‘‘hold’’ these clients in a stabilized state in which
they can respond to activating signals (Ro¨hl et al., 2013; Taipale
et al., 2010). Hsp90 chaperone activity is coupled to its ATPase
activity (Panaretou et al., 1998), which is tightly regulated by
co-chaperone proteins and post-translational modifications
(PTMs) such as phosphorylation, acetylation, ubiquitination,
and SUMOylation (covered in detail in a recent review; Walton-
Diaz et al., 2013).
Cancer cells rely on the Hsp90 chaperone machinery to pro-
tect an array of mutated and overexpressed oncoproteins from
misfolding and degradation. Thus, Hsp90 is a critical facilitator
of ‘‘oncogene addiction’’ and cancer cell survival. Emerging clin-
ical data identify Hsp90 inhibition as a promising therapeutic
strategy to treat cancer (Neckers and Trepel, 2014). Cancer cells
appear to be particularly sensitive to Hsp90 inhibitors compared
to non-transformed cells (Chiosis and Neckers, 2006), and
Hsp90 inhibitors are retained by tumors in vivo far longer than
Figure 1. Phosphorylation of a Conserved
Threonine Residue in the N-Domain of Yeast
and Human Hsp90
(A) Pymol cartoon of the Hsp90 monomer without
Sba1 (PDB: 2CG9). The cyan region represents
the N-terminal domain (NTD), yellow represents the
middle domain (MD), and orange represents the
C-terminal domain (CTD). The PreScission prote-
ase region is highlighted in pink. Alignment of yeast
and human Hsp90 showing the conservation of
T101 and T115 amino acid residues.
(B and C) N-domain phosphorylation of (B) WT
yHsp90-His6 (WT) and T101A-yHsp90-His6 (T101A)
or (C) WT hHsp90a-FLAG (WT) and T115A-
hHsp90a-FLAG (T115A) detected by immu-
noblotting with anti-hexahistidine for yHsp90 and
anti-FLAG for hHsp90a and pan-anti-phospho-
threonine antibodies after PreScission protease
digestion. IP, immunoprecipitation; Phos-Thr,
phospho-threonine.
(D) Yeast cells expressing WT yHsp90-His6 (WT) or
T101A-yHsp90-His6 (T101A) and carrying yMPS1-
MYC under GAL1-promoter were grown on raffi-
nose () or galactose (+). N-domain threonine
phosphorylation was assessed after pull-downs
and after PreScission protease digestion and
immunoblotting.
(E) yMps1 mediates threonine phosphorylation of
WT yHsp90 and T101A-yHsp90 (T101A) mutant
in vitro. Bacterially expressed and purified
yHsp90-His6 and T101A mutant were used as
substrates for yMps1. Threonine phosphorylation
was detected by immunoblotting with pan-anti-
phospho-threonine antibody. SE, short exposure;
LE, long exposure.
(F) Bacterially expressed and purified hHsp90a-
His6 and T115A mutant were used as substrates
for hMps1. Threonine phosphorylation was de-
tected by immunoblotting with pan-anti-phospho-
threonine antibody.
See also Figures S1 and S2.in normal tissues (Kamal et al., 2003). However, the molecular
basis of these phenomena remains undefined.
The mitotic checkpoint, or mitotic spindle assembly check-
point prevents missegregation of chromosomes by arresting
cells in metaphase until all chromosomes are properly aligned.
The evolutionarily conserved dual specificity protein kinase,
Mps1, is required for this process, as was recently reviewed in
detail (Liu and Winey, 2012). High expression and PTM of
Mps1 are involved in its activation, whereas the major route of
Mps1 inactivation is degradation (Liu and Winey, 2012). Overex-
pression of Mps1 also causes abnormal chromosome segrega-
tion during mitosis, i.e., aneuploidy, a hallmark of cancers
associated with high risk for tumorigenesis. (Kops et al., 2005;
Musacchio and Salmon, 2007). High levels of Mps1 kinase are
found in colon cancer tissues and several tumor cell lines such
as U937, HeLa, HEY, OCC1, Bewo, T987, and SW480 (Ling
et al., 2014; Yen and Kao, 2005).
In the present study, we found thatMps1 is highly expressed in
tumors from patients with renal cell carcinoma (RCC), including
clear cell RCC (ccRCC), papillary type I and type II RCC, oncocy-
toma, and angiomyolipoma (AML), compared to adjacent normalCtissue. Accumulation of the Hsp90 inhibitor ganetespib (GB) in
tumors from RCC patients prompted us to ask whether Mps1-
mediated phosphorylation and regulation of Hsp90 chaperone
function is themolecular basis of tumor sensitivity and selectivity
to Hsp90 inhibitors.
RESULTS
Mps1 Phosphorylates a Conserved Threonine Residue
of Yeast and Human Hsp90
Hsp90 is a post-translationally modified protein, (reviewed in
Walton-Diaz et al., 2013). Here, we show the phosphorylation
of T101 in the N-domain of yeast Hsp90 (yHsp90) by using an
assay that we have reported previously (Mollapour et al., 2011;
see Experimental Procedures) (Figures 1A and 1B). T101 was
mutated to a non-phosphorylatable alanine in yHsp90 that con-
tained a PreScission protease cleavage site between the
N-domain and the adjacent charged linker (Figure 1A). The
wild-type (WT) yHsp90 and T101A mutant were also hexahisti-
dine-tagged at their N-domains and were expressed as the
sole copies of yHsp90 in yeast. The yHsp90-His6 proteins wereell Reports 14, 872–884, February 2, 2016 ª2016 The Authors 873
isolated from cell lysates using nickel-nitrilotriacetic acid (Ni-
NTA) agarose and then treated with PreScission protease to
isolate yHsp90 N-domains. This was confirmed by western
blot analysis using anti-hexahistidine antibody. Using our previ-
ously established pan-anti-phospho-threonine antibody (Molla-
pour et al., 2011), we were able to observe the threonine
phosphorylation of yHsp90 N-domain, and this signal was signif-
icantly reduced in T101A-yHsp90 mutant (Figure 1B). We have
also previously shown the phosphorylation of T22 in the
N-domain of yHsp90 (Mollapour et al., 2011). Mutation of both
T22 and T101 to non-phosphorylatable alanine completely abol-
ished the threonine phosphorylation of N-domain yHsp90 (Fig-
ure S1A). These data suggest that T22 and T101 are the only
phospho-threonine sites in the yHsp90 N-domain.
Next, the corresponding T101 (i.e., T115) was mutated to
alanine in hHsp90a-FLAG. This mutant also contained a
PreScission site between the N-domain and the charged linker.
This allowed us to transiently express and isolate the N-domain
of hHsp90a from HEK293 cells and detect phosphorylation of
the T115 site (Figure 1C). Previous work has shown that protein
kinase C (PKC)g targets T115 in hHsp90a (Lu et al., 2014).
We showed that PKCg phosphorylates hHsp90a or yHsp90
in vitro; however, we were unable to observe PKCg-dependent
phosphorylation of T115-hHsp90a or T101-yHsp90 (Figure S1B).
Therefore, in an attempt to identify the kinase(s) targeting T101/
T115, we used the yeast deletion library for the non-essential ki-
nases (110 strains) obtained from EUROSCARF (http://www.
euroscarf.de/search.php?name=Order) (Figures S2A and S2B;
Table S1). The yeast essential kinases library (19 kinases) under
the control of the GAL1-promoter was obtained from Dharma-
con (http://dharmacon.gelifesciences.com/). These libraries
were transformed with either WT yHsp90 or T101A mutant (con-
taining the PreScission site), and then the levels of N-domain
phosphorylation were assessed by western blot analysis (Fig-
ures S2C and S2D). We found that only overexpression of the
essential protein kinase Mps1 causes an increase in the phos-
phorylation of T101-yHsp90 (Figure 1D). Next, we used purified
recombinant yeast Mps1 (yMps1) in an in vitro kinase assay
with bacterially expressed and purified WT yHsp90 and T101A
mutant. Our data showed that yMps1 phosphorylates only the
T101 in yHsp90 in vitro (Figure 1E). Since Mps1 is an evolution-
arily conserved protein kinase (Abrieu et al., 2001), we used
the purified human Mps1 (hMps1), also known as PYT/TTK in
an in vitro kinase assay. hMps1 phosphorylates only the T115
residue in hHsp90a in vitro (Figure 1F).
T101/T115 Phosphomutants Affect Hsp90 ATPase
Activity and Co-chaperone Binding
The chaperone activity of Hsp90 is coupled to its ability to bind
and hydrolyze ATP (Panaretou et al., 1998). Therefore, we ex-
pressed and isolated yHsp90 and the phosphomutants from
yeast and determined their ATPase activity, using a small-scale
PiPer Phosphate Assay (Thermo Fisher Scientific) as previously
described (Kamal et al., 2003) (see Experimental Procedures).
T101A had a similar (80%) ATPase activity compared to the
WT yHsp90, whereas the T101E-yHsp90 ATPase was reduced
by 62% (Figure S3A). Next, we expressed and purified yHsp90
and hHsp90a from bacteria and phosphorylated them in vitro874 Cell Reports 14, 872–884, February 2, 2016 ª2016 The Authorsusing recombinant yMps1 and hMps1, respectively (Figures
S3B and S3C). The ATPase activity of the phosphorylated
and non-phosphorylated Hsp90 proteins were determined
using the aforementioned method. Consistent with our earlier
result, Mps1-mediated phosphorylation of Hsp90 reduced the
ATPase activity of yHsp90 by 69% and of hHsp90a by 59% (Fig-
ures 2A and 2B; Figures S3D–S3F).
Next, we examined the interaction of several important regula-
tory Hsp90 co-chaperones with T101-yHsp90 and T115-
hHsp90a phosphomutants. Lysates of yeast expressing WT
yHsp90, T101A, or T101E were subjected to affinity pull-down
with Ni-NTA agarose, and interacting co-chaperones were
examined by western blot analysis. The interaction of both mu-
tants with yAha1 was abolished, interaction with Cdc37p50 was
significantly enhanced, and interaction with Sti1HOP was un-
changed (Figure 2C). In contrast, association of Sba1p23 with
T101A was lost, but its interaction with T101E was slightly
enhanced compared to the WT yHsp90 (Figure 2D). We also ob-
tained similar results with mammalian co-chaperones. HEK293
cells were transiently transfected with FLAG-hHsp90a or its
T115A or T115E mutants. WT hHsp90a and its mutants inter-
acted with p60HOP with similar affinity, while the mutants bound
slightly stronger to p50Cdc37 as compared to WT (Figure 2D).
However, association of both mutants with human Aha1
(hAha1) was abolished, and T115A interaction with p23 was
significantly reduced (Figure 2D). Taken together, our data sug-
gest that phosphorylation of T101/T115 is a dynamic process
that stabilizes N-domain dimerization and Sba1p23 association,
which itself is known to slow the rate of ATP hydrolysis (Siligardi
et al., 2004). It follows that dephosphorylation of T101/T115 is
necessary to permit ATP hydrolysis.
Phosphorylation of T101/T115 Selectively Impacts the
Chaperoning of Clients
The importance of the T101 residue on chaperone activity was
first reported 20 years ago (Nathan and Lindquist, 1995). Here,
we tested the ability of T101-yHsp90 phosphomutants to
chaperone known endogenous clients in yeast. The mitogen-
activated protein kinase (MAPK) kinase Mpk1/Slt2 (an Erk5
ortholog) is an Hsp90 client. Activation of this kinase with
heat shock or caffeine stress strengthens its interaction with
yHsp90 (Truman et al., 2006). Mpk1/Slt2 from heat-shocked
yeast cells (39C for 40 min) or yeast stressed with 10 mM
caffeine interacts with yHsp90. These stresses activate the cell
wall integrity pathway in yeast. However, interaction of Mpk1/
Slt2 with T101A-yHsp90 was significantly reduced (Figure 3A).
Conversely T101E-yHsp90 associated with Mpk1/Slt2, even in
the absence of stress (Figure 3A). We observed similar data
with another endogenous yeast Hsp90 client, active Ste11 ki-
nase (Ste11DN), the ortholog of mammalian Raf-1 (Flom et al.,
2008; Louvion et al., 1998). The non-phosphorylatable T101A
was unable to interact with the active Ste11 kinase, while asso-
ciation of the phosphomimic T101E mutant with active Ste11
was slightly enhanced compared to wild-type Hsp90 (Figure 3B).
Next, we examined the impact of T101 phosphomutants on
the chaperoning of two non-kinase clients. The mammalian
glucocorticoid receptor (GR) is a well-characterized Hsp90 client
that provides an Hsp90 functional assay in yeast (Pratt et al.,
Figure 2. Impact of T101-yHsp90 and T115-
hHsp90a Phosphorylation on ATPase Activ-
ity and Co-chaperones Binding
(A) Relative ATPase activity of WT yHsp90-His6
and yMps1 mediated phospho-T101-yHsp90-
His6. ATPase activity was inhibited by 10 mM GB.
Error bars represent SD of three independent ex-
periments. ****p < 0.0001.
(B) Relative ATPase activity of WT hHsp90a-His6
and hMps1 mediated phospho-T115-hHsp90a-
His6. ATPase activity was inhibited by 10 mM GB.
Error bars represent SD of three independent ex-
periments. ****p < 0.0001.
(C) yHsp90 was isolated from yeast with empty
plasmid (C), WT yHsp90-His6 (WT), T101A-
yHsp90-His6 (T101A), and T101E-yHsp90-His6
(T101E). Interaction of the co-chaperones yAha1,
Cdc37p50, Sba1p23, and Sti1Hop were detected
by immunoblotting. Equivalent precipitation of
yHsp90 was confirmed by blotting for hex-
ahistidine.
(D) HEK293 cells were transfected with empty
plasmid (C), hHsp90a-FLAG (WT), T115A-
hHsp90a-FLAG (T115A), or T115E-hHsp90a-FLAG
(T115E). Hsp90-FLAG was immunoprecipitated
(IP) with anti-FLAG M2 affinity gel and interaction
with hAha1 or p50cdc37, p23Sba1, or p60Hop was
examined by immunoblotting.2004). WT yeast cells, as well as the T101A and T101E mutants,
were transformed with plasmids constitutively expressing GR
and a glucocorticoid-regulated lacZ reporter gene (Garabedian
and Yamamoto, 1992). In this case, the GR activity was almost
four times higher in the T101A mutant than in the WT cells;
conversely, the phosphomimetic T101E mutant showed
impaired GR activity (Figure 3C). Next, we tested the effect of
T101 phosphorylation on Heat shock factor-1 (Hsf1) transcrip-
tional activity. Hsf1 is an Hsp90 client, and its interaction with
this chaperone suppresses Hsf1 activity (Zou et al., 1998).
Hsp90 inhibition, due to mutation or pharmacologic inhibition,
leads to induction of Hsf1 activity in the absence of heat shock
stress (Hjorth-Sørensen et al., 2001). Temperature sensitivity of
the T101Imutant has been reported previously (Nathan and Lind-
quist, 1995). Here, we showed the phosphomutant T101E to be
temperature sensitive (ts) at 30C and T101A at 37C (Figure 3D).
The heat shock response in the T101A mutant upon heat stress
was 1.5-fold higher than in WT yeast cells but was 2-fold lower
than inWT for the T101Emutant (Figure 3E). We observed similar
results with T115-hHsp90a phosphomutants. HEK293 cells were
transiently co-transfected with the Hsp90 kinase client, ErbB2,
and one of the following constructs: WT hHsp90a-FLAG,
T115A, or T115Emutants. While wewere able to co-immunopre-
cipitate ErbB2 with the WT hHsp90a-FLAG, ErbB2 interactionCell Reports 14, 872–884with T115Awas significantly reduced (Fig-
ure 3F). We obtained similar data with
endogenous Cdk4 (another Hsp90 kinase
client) (Figure 3F). Interaction of the phos-
phomimetic mutant T115E with both
ErbB2 and Cdk4 was slightly increased
(Figure 3F). Consistent with our observa-tion in yeast, T115A-hHsp90a interaction with GR was signifi-
cantly increased, whereas T115E-hHsp90a association with GR
was completely abolished (Figure 3G). These data show that
phosphorylation of T101/T115 increases the interaction with,
and activity of, several kinase clients but inhibits the interaction/
activity of the steroid hormone receptor GR.
Phosphorylation of T101/T115 Is Essential for Mps1
Activity and Mitotic Checkpoint
Previous work has suggested that co-chaperones Cdc37 and
Sti1 are involved in the chaperoning of yMps1 (Schutz et al.,
1997). We evaluated whether Mps1 is an Hsp90 client and also
examined the impact of T101/T115 phosphorylation on the
chaperoning of Mps1 itself. Treating the yeast cells with 40 mM
GB, an Hsp90 inhibitor, led to degradation of the endogenously
Myc-epitope-tagged yMps1 protein (Figure 4A). This phenome-
non was reversed by pre-treating the yeast cells with the protea-
some inhibitor MG132 (Figure 4B). We next evaluated yMps1
protein stability in Hsp90-T101 phosphomutants by cyclohexi-
mide (CHX) chase analysis and found that yMps1-Myc was
markedly stable in WT and T101E yeast cells. Conversely,
yMps1-Myc expressed in the non-phosphorylatable T101A
mutant background was undetectable after 60-min treatment
with cycloheximide (Figure 4C)., February 2, 2016 ª2016 The Authors 875
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Figure 3. Threonine Phosphorylation of the
Hsp90 N-Domain Impacts the Chaperoning
of Clients
(A) Interaction of WT yHsp90-His6 (WT), T101A-
yHsp90-His6 (T101A), and T101E-yHsp90-His6
(T101E) mutants with Mpk1/Slt2 was examined
after yeast cells were stressed with 10 mM
caffeine or heat shocked at 39C for 60 min
(activator of Mpk1/Slt2 MAP kinase). Empty
plasmid was used as a control (C). yHsp90-His6
isolated by Ni-NTA and interaction with Mpk1/Slt2
were examined by immunoblotting.
(B) WT yHsp90-His6 (WT), T101A, and T101E
yeast strains transformed with Ste11DN-His6 un-
derGAL1-promoter were grown on raffinose () or
galactose (+) media, and Ste11DN-His6 protein
expression was examined by immunoblotting.
a-tubulin was used as loading control.
(C) GR-lacZ activity was assessed in the same
yeast strains as described above. Data are ex-
pressed as a percentage of the activity inWT cells,
and results from three independent experiments
are depicted as the mean ± SD. **p < 0.005.
(D) A 1:10 dilution series of 107 cells per ml of
WT yHsp90-His6 (WT), T101A, and T101E yeast
strains were spotted on YPDA agar. Plates were
incubated at 25C, 30C and 37C for 3 days.
(E)WT yHsp90-His6 (WT), T101A, and T101E yeast
strains expressing heat shock element (HSE)-lacZ
were heat shocked (40 min at 39C). Heat shock
response was measured in three independent ex-
periments. All data representmean±SD. *p < 0.05.
(F) SkBr3 cells were transfected with empty
plasmid (C), hHsp90a-FLAG (WT), T115A-
hHsp90a-FLAG (T115A), or T115E-hHsp90a-FLAG
(T115E). Hsp90-FLAG was immunoprecipitated
(IP) with anti-FLAG M2 affinity gel, and co-immu-
noprecipitated ErB2 and Cdk4 were detected by
immunoblotting. Phos-Thr, phospho-threonine.
(G) HEK293 cells were transfected with indicated
Hsp90 constructs. Hsp90-FLAG was immuno-
precipitated with anti-FLAG M2 affinity gel, and
co-immunoprecipitated GR was detected by
immunoblotting.Next, we examined the interaction of yMps1 with the T101
phosphomutants. The interaction of the non-phosphorylatable
T101A mutant with yMps1-Myc was completely abrogated. In
contrast, the interaction between T101E and yMps1-Myc was
stronger than the interaction between WT yHsp90 and yMps1
(Figure 4D). We obtained similar results with the WT hHsp90a
and the T115 phosphomutants. The T115A mutant was unable
to bind to hMps1, whereas the phosphomimetic T115E associ-
ated more strongly than WT hHsp90a with hMps1 (Figure 4E).
Our data suggest a model in which Mps1-mediated phosphory-
lation of T101/T115 enhances its interaction with Hsp90,
possibly increasing Mps1 kinase activity.
To test these hypotheses, we isolated Mps1-Myc from yeast
expressing WT yHsp90 and T101 phosphomutants and used
pan-phospho-threonine antibody to examine the autophosphor-
ylation/activity of yMps1. Threonine phosphorylation of yMps1
was detected in WT yeast cells and was increased in the
T101E mutant. However yMps1 phosphorylation was signifi-
cantly reduced in the T101A mutant (Figure 4F). Our data876 Cell Reports 14, 872–884, February 2, 2016 ª2016 The Authorssuggest that yMps1 activation and phosphorylation of T101-
yHsp90 facilitates the interaction of yMps1 with yHsp90, which,
in turn, is important for maintaining yMps1 kinase activity.
We decided to test this model further by determining whether
the T101E yeast cells experience mitotic arrest. Previous work
has shown that overexpression of yMps1 causes cell cycle arrest
at G2 but with morphologically normal spindles (Hardwick et al.,
1996). Here, we examined yeast cells expressing WT yHsp90,
T101A, or T101E mutants for any cell cycle defect and discov-
ered that T101E mutant yeast were arrested in G2 (Figure 4G).
Next, we overexpressed yMps1-GST under the GAL1-promoter
in WT or T101A mutant yeast. Cells were grown on media con-
taining raffinose in order to suppress the GAL1-promoter and
then shifted to galactose-containing media to induce the
GAL1-promoter. In agreement with previous reports (Hardwick
et al., 1996), overexpression of yMps1 arrested WT cells in G2,
but it had no effect in T101A mutant yeast (Figure 4H). Mps1 ki-
nase is essential for the mitotic checkpoint (also known as the
spindle checkpoint); therefore, Mps1 deletion is lethal in yeast
Figure 4. Mps1-Mediated Phosphorylation
of Hsp90 Is Essential for Mitotic Arrest
(A) WT yHsp90-His6 yeast cells with endogenously
Myc-epitope-tagged yMps1 were treated with
40 mM GB for indicated time points in liquid YPDA
media. The stability of yMps1-Myc was assessed
by immunoblotting.
(B) WT yHsp90-His6 yeast cells with endogenous
yMps1-Myc were treated with either 40 mM GB for
24 hr or 50 mM proteasome inhibitor MG132 for
24 hr. Cells were also pretreated with MG132 1 hr
prior to treatment with GB.
(C) Yeast cells expressing yHsp90-His6 (WT),
T101A, and T101E with endogenous yMps1-Myc
were treated with 100 mg/ml CHX. yHsp90-His6
and yMps1-Myc proteins were detected by
immunoblotting at the indicated times. Data were
also quantified and presented as bar charts. Error
bars represent SD. OD, optical density.
(D) Yeast with yHsp90-His6 (WT), T101A-yHsp90-
His6 (T101A), and T101E-yHsp90-His6 (T101E)
mutants with endogenous yMps1-Myc were used
to isolate yHsp90-His6 by Ni-NTA, and interaction
of yMps1 was examined by immunoblotting.
Empty plasmid was used as a control (C).
(E) HEK293 cells were transfected with empty
plasmid (C), hHsp90a-FLAG (WT), T115A-
hHsp90a-FLAG (T115A), or T115E-hHsp90a-
FLAG (T115E). Hsp90-FLAG was immunoprecipi-
tated (IP) with anti-FLAG M2 affinity gel, and
interaction of human Mps1 was examined by
immunoblotting.
(F) yMps1-Myc was isolated from yeast cells ex-
pressing yHsp90-His6 (WT), T101A-yHsp90-His6
(T101A), and T101E-yHsp90-His6 (T101E). yMps1
activity was examined by immunoblotting using
pan-phospho-threonine antibody.
(G) Flow cytometry analysis of yHsp90-His6 (WT),
T101A-yHsp90-His6 (T101A), and T101E-yHsp90-
His6 (T101E) mutants grown in liquid YPDA over-
night at 25C. 57%ofWT, 54%of T101A, and 77%
of T101E cells were arrested in G2.
(H) yHsp90-His6 (WT) and T101A-yHsp90-His6
(T101A) cells containing GAL-yMPS1-GST were
grown in liquid YP-raffinose overnight at 25C and
then transferred to YP-galactose for 2 hr at 25C. Flow cytometry analysis revealed only WT cell accumulation in G2 (75%).
(I) Budding morphology of distributions in WT, T101, andmps1-1 yeast mutants. Cells were arrested in G1 with an a-factor at 25C and then released in medium
containing 20 mg/ml nocodazole for 4 hr at either 25Cor 37C. 100 cells were scored for large buds (L), multiply budded (M), and unbudded (U). Cells were scored
from three independent experiments.
All data represent mean ± SD. **p < 0.005.(Abrieu et al., 2001). The ts mps1-1 mutant is viable at the
permissive temperature (25C). We synchronized the WT,
mps1-1, and T101A-yHsp90 yeast cells in G1, with an a-factor
at 25C. The cells were then released in medium containing the
microtubule poison nocodazole, a known activator of the mitotic
checkpoint, for a further incubation of 4 hr at either 25C or 37C.
WT, mps1-1, and T101A cells were arrested with large buds in
nocodazole-containing medium at 25C (Figure 4I). In contrast,
after 4 hr in medium containing nocodazole at 37C, T101A mu-
tants, like mps1-1 yeast, had multiple-budded cells (Figure 4I).
Taken together, our data suggest that Mps1 phosphorylation
of T101-yHsp90 is essential for its kinase activity and also for
mitotic arrest.CQuantitative Proteomic Analysis of Phosphorylated
Hsp90
Our data have shown that phosphorylation of T101 promotes
Hsp90 interaction with certain client proteins. In order to quanti-
tatively identify the global interactome of Hsp90 as the result
of T101 phosphorylation, we purified the T101A and T101E-
yHsp90-His6 interactomes and compared them by isotope-
coded liquid chromatography-tandem mass spectrometry (LC-
MS/MS; Figure 5A). Based on high-confidence peptidematches,
474 yHsp90 partners were identified (Table S2). Gene Ontology
(GO) analysis of these interactors revealed ‘‘response to stress’’
and ‘‘protein dephosphorylation’’ as the most enriched cate-
gories for increased association and ‘‘cytoplasmic translation’’ell Reports 14, 872–884, February 2, 2016 ª2016 The Authors 877
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Figure 5. T101 Phosphorylation Alters the
yHsp90 Interactome
(A) A schematic illustration of the methodology
used to identify the yHsp90 interactome. Cells
expressing either T101A- or T101E-yHap90-His6
were grown tomid log. yHsp90 complexes purified
via immobilized metal ion affinity chromatography
(IMAC) and trypsinized. T101E-yHsp90-His6 in-
teracting peptides were isotopically labeled with
18O, mixed 1:1 with T101A-yHsp90-His6 interact-
ing peptides, and then analyzed by quantitative
LC-MS/MS.
(B) GO term analysis of yHsp90 interactors. They
were classified by cellular process using GO Slim.
Enrichment for each process is shown relative to
occurrence in non-essential genome.
(C) Effect of T101 phosphorylation on yHsp90 in-
teractome. yHsp90 interactors were grouped into
non-redundant functional categories. Interactions
are colored based on change; white nodes
represent unchanged interactions, red nodes are
significantly increased interactions, and green
nodes are significantly decreased interactions.as the most enriched category for dissociation (Figure 5B). Next,
we analyzed individual proteins that were associated or dissoci-
ated with yHsp90 as the result of T101 phosphorylation. A large
number of ribosomal proteins involved in ‘‘transcription/transla-
tion’’ were dissociated from yHsp90; surprisingly, there was no
change in protein interactions involved in ‘‘chromatin regulation’’
(Figure 5C). We also discovered that T101 phosphorylation
enhanced yHsp90 interaction with Cdc55, but it enhanced
dissociation from Cdc14, grouped under the ‘‘cell cycle’’ node
(Figure 5C). Cdc55 phosphatase promotes mitotic entry (Healy
et al., 1991; Wang and Burke, 1997), whereas Cdc14 phospha-
tase is required for mitotic exit (Bremmer et al., 2012; Mocciaro
and Schiebel, 2010).
Cdc14 Dephosphorylates T101 and Disrupts yMps1-
yHsp90 Complex
To determine whether either Cdc55 or Cdc14 is involved in the
dephosphorylation of T101, we overexpressed glutathione
S-transferase (GST)-epitope-tagged Cdc55 and Cdc14 under a878 Cell Reports 14, 872–884, February 2, 2016 ª2016 The Authorsgalactose-inducible promoter (GAL1-pro-
moter) in yeast with either WT yHsp90-
His6 or T101A mutant. After inducing
CDC55-GST or CDC14-GST expression
by growing the cells on medium contain-
ing galactose for 2 hr, we detected both
proteins by western blot analysis using
anti-GST antibody (Figures 6A and 6B).
Next, we examined the phosphorylation
status of T101 in the N-domain of
yHsp90 using the PreScission cleavage
procedure (Mollapour et al., 2011). Over-
expression of Cdc55 did not change the
threonine phosphorylation of N-domain
yHsp90, whereas overexpression of
Cdc14 reduced the threonine phosphory-lation of the N-domain (Figures 6A and 6B). To investigate
whether Cdc14 directly targets T101, we used bacterially
expressed and purified WT yHsp90-His6 and T101A mutant
bound to Ni-NTA agarose. We also overexpressed and purified
GAL1-yMPS1-MYC from yeast by immunoprecipitation. Purified
yMps1-Myc was salt-stripped with 0.5 M NaCl to disrupt co-
immunoprecipitated proteins. We found that yMps1 phosphory-
lates only T101 in yHsp90 (Figure 6C). Our in vitro data also
showed that T101A-yHsp90 mutant did not form a complex
with yMps1. This result suggests that yMps1 only targets
T101, and this is essential for yHsp90-yMps1 complex forma-
tion (Figure 6C). These data are in agreement with our in vivo
findings (Figure 4D). Next, we incubated the phosphorylated
T101-yHsp90 with immunoprecipitated and salt-stripped
Cdc14-GST from yeast. This phosphatase had the ability to
dephosphorylate T101 and then form a strong complex with de-
phosphorylated yHsp90. Interestingly, yMps1 was dissociated
from yHsp90 under these conditions (Figure 6C). We confirmed
these data by isolating hexahistidine-epitope-tagged yHsp90
Figure 6. Cdc14 Phosphatase Targets
yHsp90 and Dephosphorylates T101
(A and B) Yeast expressing WT yHsp90-His6 (WT)
and carrying (A) CDC55-GST or (B) CDC14-GST
underGAL1-promoter were grown on YP-raffinose
() overnight at 25C and then shifted to YP-
galactose (+) for 2 hr at 25C. N-domain threonine
phosphorylation of yHsp90 was assessed after
pull-downs, PreScission protease digestion, and
immunoblotting. Phos-Thr, phospho-threonine.
(C) yMps1-Myc was isolated from yeast, salt-
stripped (0.5 M NaCl), and used to phosphorylate
bacterially expressed and purified yHsp90-His6
(WT) and T101A-yHsp90-His6 (T101A). Cdc14-
GST isolated from yeast, salt-stripped (0.5 M
NaCl), and used to dephosphorylate T101. Total
and phosphorylated yHsp90 was detected by
immunoblotting.
(D) Yeast cells with yHsp90-His6 (WT), T101A-
yHsp90-His6 (T101A), and T101E-yHsp90-His6
(T101E) mutants were isolated by Ni-NTA,
and interaction of Cdc14 was examined by
immunoblotting. Empty plasmid was used as a
control (C).
(E) Yeast cells were released from G1 (2.5 mg/ml
a-factor) to mitosis (20 mg/ml nocodazole) or from
mitosis to G1 and then analyzed by flow cytometry
every 15 min.
(F)Phosphorylationof theN-yHsp90-His6 (WT) from
cells in (E) was analyzed by immunoblotting with
pan-anti-phospho-threonine antibody. Cdc14,
yMps1-Myc and full-length yHsp90-His6 protein
levels were also detected by immunoblotting.
(G) Schematic representation of yMps1-mediated
phosphorylation and Cdc14-facilitated dephos-
phorylation of T101-yHsp90. (1) yMps1 binds
to yHsp90 and phosphorylates T101, and this
promotes formation of yHsp90:yMps1 complex.
(2) Cdc14 mediates dephosphorylation of T101, (3)
disrupts yHsp90:yMps1 complex, and promotes
yHsp90:Cdc14 association. (4) Possible dissocia-
tion of Cdc14 allows yMps1 binding and restarting
the phosphorylation cycle.proteins from cell lysates using Ni-NTA agarose beads. The
endogenous Cdc14 interaction with yHsp90 was assessed by
immunoblotting using anti-Cdc14 antibody (Figure 6D). Cdc14
interacted with the WT yHsp90, and this association was
significantly enhanced with the non-phosphorylatable T101A
mutant (Figure 6D). Conversely, the phosphomimetic T101E
mutant did not associate with the Cdc14-GST. Our data sug-
gest that phosphorylation/dephosphorylation of T101-Hsp90
may be part of the regulation of the cell cycle. We validated
this point by synchronizing yeast cells in G1 using an a-factor
and then releasing in media containing nocodazole in order to
arrest the cells in mitosis (early anaphase) (Figure 6E).
Conversely, yeast cells were also arrested in mitosis and then
released in media with an a-factor. Cell cycle status was exam-
ined every 15 min. Next, we isolated the N-domain yHsp90-
His6 by using the PreScission protease cleavage and monitored
the phosphorylation of T101 by western blot analysis. Our
earlier data have shown that T22 and T101 are the only phos-Cpho-threonine sites in the yHsp90 N-domain (Figure S1A).
Since T22 phosphorylation does not change at different stages
of the cell cycle (Mollapour et al., 2011), we concluded that the
change in the threonine phosphorylation of N-domain yHsp90
is because of the modification of T101. Our data show that
T101 is not phosphorylated in G1, and as cells undergo mitosis,
the levels of T101 phosphorylation increases significantly (Fig-
ure 6F). This is consistent with yMps1 increase in mitosis and
absence of the phosphatase Cdc14 from G1 to mitosis (Fig-
ure 6F). Next, we examined T101 phosphorylation in cells exit-
ing mitosis and entering G1. As yeast cells exit mitosis, the
yMps1 level decreases, coinciding with an increase in the
Cdc14 (Figure 6F).
Taken together, our findings suggest that yMps1 phosphory-
lates T101-yHsp90, and this is essential for the mitotic
checkpoint (Figure 6G). The Cdc14 phosphatase, in turn, de-
phosphorylates T101 and dissociates yHsp90-yMps1 complex,
leading to its inactivation.ell Reports 14, 872–884, February 2, 2016 ª2016 The Authors 879
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Figure 7. Mps1-Mediated Phosphorylation
of Hsp90 Sensitizes Cells to Hsp90 Drugs
and Confers Tumor Selectivity to Hsp90 In-
hibitors
(A) Yeast expressing yHsp90-His6 (WT), and indi-
cated phospho-T101 mutants were spotted at a
1:10 dilution series of 107 cells per milliliter on
YPDA agar containing 60 mM Hsp90 inhibitor
SNX2112 or GB. Plates were incubated at 28C for
4 days.
(B) Strains in (A) containing either empty plasmid
(pYES2) or GAL-yMps1-MYC were grown on
raffinose media overnight at 25C. A 1:10 dilution
series of 107 cells per ml were spotted on YPDA or
YPGAL agar containing 60 mM SNX2112 or GB.
Plates were incubated at 28C for 4 days.
(C) HEK293 cells were transiently transfected with
empty plasmid (C) or hMps1-FLAG. Protein
expression was assessed by immunoblotting.
(D) Lysates from (C) were incubated with indicated
amounts of biotinylated-GB, followed by strepta-
vidin agarose beads, and Hsp90 was detected by
immunoblotting.
(E–J) Adjacent normal tissues and (E) ccRCC , (F
and G) papillary type I, (H) papillary type II, (I) on-
cocytoma, and (J) AMLwere dissected into 3-mm3
pieces that were cultured in medium containing
10 mM NMS-P715 (Mps1 inhibitor) for 24 hr. Tis-
sues were then incubated with 0.5 mM BODIPY
fluorophore-conjugated GB (STA-12-9455; GB-
Green-FL) for an additional 6 hr. Tissueswere fixed
and immunostained for either Hsp90 (hHsp90-Red
FL), or hMps1 (hMps1-Red FL). DNA was stained
with DAPI for immunofluorescence analysis.
See also Figure S4.Elevated hMps1 Levels in RCC Confer Selectivity to
Hsp90 Inhibitors
Although Hsp90 is highly expressed in most cells, Hsp90 inhibi-
tors selectively kill cancer cells compared to normal cells. We
observed that the T101E phosphomimetic yeast mutant is sensi-
tive to the pharmacologic Hsp90 inhibitors geldanamycin and
radicicol, as well as to the clinically evaluated Hsp90 inhibitors,
SNX2112 and GB (Figure 7A; Figure S4A). Overexpression of
yMps1 in yeast also conferred sensitivity to both SNX2112 and
GB (Figure 7B). This sensitivity was not observed in the T101A
mutant, suggesting that yMps1-mediated phosphorylation of
T101 is essential for the drug sensitivity. We further validated
this finding by transiently overexpressing hMps1-FLAG in
HEK293 cells (Figure 7C), and consequently enhancing WT
hHsp90 (both a and b isoforms) binding to biotinylated-GB (Fig-
ure 7D). These data suggest that hyperphosphorylation of T101
or T115, as the result of overactive Mps1, sensitizes yeast and
mammalian cells to Hsp90 inhibitors.
Hsp90 inhibitors selectively accumulate in cancer cells
compared to normal cells. Therefore, we tested for possible880 Cell Reports 14, 872–884, February 2, 2016 ª2016 The Authorsoverexpression of Mps1 in tumors that
could account for this observation. We
used tumors and adjacent normal tissues
from patients with RCC. Based on histo-pathology, RCCs are classified into multiple types. We used tu-
mors frompatients with ccRCC, papillary type I and type II RCCs,
oncocytoma, and AML (Figure S4B). Within 15 min of removal of
tumors, by radical or partial nephrectomy, human RCC tumors
were dissected into 3-mm3 pieces and cultured in medium con-
taining 10 mM NMS-P715 (a potent Mps1 inhibitor) (Colombo
et al., 2010) for 24 hr. The tumors were incubated with 0.5 mM
BODIPY fluorophore-conjugated GB (STA-12-9455; FL-GB) for
an additional 6 hr.
Tissues were fixed, and accumulation of FL-GBwas examined
by confocal immunofluorescence microscopy. The tissues were
co-stained with hHsp90 and hMps1. As expected, the FL-GB
(green fluorescent) was primarily accumulated in the tumors
but not in the normal tissues (Figures 7E–7J). hMps1 level (red
fluorescent) was also elevated in tumors compared to the level
in the normal tissues (Figures 7E–7J). However, treating the tu-
mors with the hMps1 inhibitor NMS-P715 abolished the accu-
mulation of FL-GB (Figures 7E–7J). It is noteworthy that
hHsp90 levels (red fluorescent) were unaffected in the normal
and tumor tissues, even after treatment with NMS-P715 (Figures
Figure 8. Overexpression ofMps1 in RCC In-
creases Hsp90 Binding to GB
(A–F) ccRCC (A), papillary type I (B and C), papillary
type II (D), oncocytoma (E), and AML (F) tissues
were cultured in medium with 10 mM NMS-P715
(Mps1 inhibitor) or without drug for 24 hr. After
protein lysate preparation, Hsp90 binding to GB
was assessed by biotinylated-GB and immuno-
blotting.
(G) Hsp90 in samples (A)–(F) was detected by
immunoblotting using anti-Hsp90-antibody.
(H) Overexpression and hyperactivity of Mps1 in
kidney tumor compared to the adjacent normal
tissue confer cancer cell selectivity and sensitivity
to Hsp90 inhibitor GB.7E–7J); however, hMps1 levels were significantly reduced in the
NMS-P715-treated tumors (Figures 7E–7J).
We further validated these data by examining the affinity of
hHsp90 from the normal and tumor tissues for binding to bio-
tinylated-GB. We discovered that the hHsp90 from tumors had
a higher affinity for biotinylated-GB compared to the adjacent
normal tissues (Figures 8A–8F). Tumors treated with the
hMps1 inhibitor NMS-P715 reduced the binding of hHsp90 to
biotinylated-GB (Figures 8A–8G). Taken together, our data sug-
gest that overexpression of Mps1 can account for tumor sensi-
tivity and tumor selectivity of Hsp90 inhibitors (Figure 8H).
DISCUSSION
In this study, we documented the phosphorylation of a single
conserved threonine residue in the N-domain of both yeast
(T101) and mammalian (T115) Hsp90. Previous work has shown
that T101I has an ATP affinity similar to that of theWT yHsp90 but
reduced ATPase activity and AMP-PNP-dependent N-domainCell Reports 14, 872–884dimerization (Prodromou et al., 2000).
T101 is located within the lid segment of
yHsp90, and in the ‘‘open’’ conformation,
the side chain of T101 packs into a hydro-
phobic cavity formed by the side chains of
I12 and L15 and by the Ca and Cb of E11.
Upon N-domain dimerization, this interac-
tion is disrupted and exposes the side
chain of T101 on the top surface of the
lid. Mutations to alanine or glutamic acid
stabilize the hydrophobic interaction in
the ‘‘open’’ conformation and destabilize
the exposure of the side chain in the
‘‘closed’’ conformation. Our data show
that phosphorylation of T101 significantly
reduces the yHsp90 ATPase activity,
whereas lack of phosphorylation has min-
imum impact on ATP hydrolysis in yeast.
In terms of interaction with co-chaper-
ones, neither non-phosphorylatable nor
phosphomimic mutants in yeast or human
Hsp90 bound to Aha1; however, both mu-
tants had a strong interaction with Cdc37.Phosphorylation of Hsp90 also enhanced binding and chaper-
oning of several kinase clients while reducing the activity of the
non-kinase client GR.
Recent work has shown that PKCg phoshorylates T115-
hHsp90a (Lu et al., 2014). We were unable to verify these results
using both yeast and human Hsp90 proteins in an in vitro kinase
assay. We were also unable to show yeast PKC1-mediated
phosphorylation of T101 in yeast overexpressing PKC1.
We screened the yeast non-essential kinase deletion as well
as essential kinase overexpression libraries and identified
yMps1 as the kinase targeting T101-yHsp90. yMps1 is an evolu-
tionarily conserved dual-specificity protein kinase required for (1)
duplication of centrosomes in metazoans or spindle pole body
(SPB) in yeast and (2) the mitotic spindle assembly checkpoint
(also known as the mitotic checkpoint) (Liu and Winey, 2012).
However, its primary cellular substrate has remained elusive.
Previous work has demonstrated that yMps1 activity requires
the co-chaperone Cdc37 (Schutz et al., 1997). yMps1 is essential
in eukaryotic cells, and it was shown that both conditional and, February 2, 2016 ª2016 The Authors 881
non-conditional alleles of cdc37 are lethal in combination with
the mps1-1 ts mutant in yeast (Schutz et al., 1997). Winey’s lab
has also reported that mutations in yHSP90 and in the co-chap-
erones YDJ1 and STI1 display synthetic lethality with themps1-1
mutation (Jones et al., 1999). Our data show that Mps1 is a bona
fide Hsp90 client, and its phosphorylation of T101-yHsp90 and
T115-hHsp90a is required for mitotic arrest. Our data also
show that yMps1 does not stably interact with the non-phos-
phorylatable T101A-yHsp90 mutant, suggesting that yMps1-
mediated phosphorylation stabilizes interaction of this kinase
with Hsp90. It is noteworthy that our proteomic data did not
identify yMps1 interaction with T101E-yHsp90. This might be
because of the low abundance of yMps1 kinase in cells (Liu
andWiney, 2012). Our quantitative proteomic analysis, however,
identified the Cdc14 phosphatase responsible for dephosphory-
lation of T101. Our data suggest a regulatory paradigm in which
Mps1 phosphorylation of Hsp90 leads to formation of a strong
complex between these two proteins and, consequently, causes
mitotic arrest. The Cdc14 phosphatase dephosphorylates T101
and disrupts the Mps1-Hsp90 complex. This leads to the degra-
dation of Mps1. We posit that this process is vital for mitotic exit,
since Cdc14 phosphatase activity is essential for this step.
Mps1 kinase activity is essential for spindle checkpoint
signaling (Hardwick et al., 1996). Overexpression of Mps1 is
coupled to an increase in its kinase activity and it causes
abnormal chromosome segregation during mitosis, i.e., aneu-
ploidy, a hallmark of cancers associated with high risk for tumor-
igenesis. (Kops et al., 2005; Musacchio and Salmon, 2007). We
found that overexpression of yMps1 made yeast cells sensitive
to Hsp90 inhibitors, and this phenotype depends on the phos-
phorylation of T101. Also, overexpression of hMps1 in mamma-
lian cells increased their binding to GB.
High levels of hMps1 kinase are found in colon cancer tissues
and several tumor cell lines such as U937, HeLa, HEY, OCC1,
Bewo, T987, and SW480 (Ling et al., 2014; Yen and Kao,
2005). Here, we observed high levels of hMps1 in different kidney
tumors (ccRCC, AML, oncocytoma, papillary type 1 and type 2
RCCs) compared to the adjacent normal tissue. We also found
that the Hsp90 inhibitor GB selectively accumulates in these tu-
mor specimens. However, pharmacologic inhibition of hMps1
prevented the accumulation of GB in the tumor tissue, suggest-
ing that high expression/activity of hMps1 may be characteristic
of some cancers and can potentially serve as a predictive indica-
tor of tumor response to Hsp90 inhibitors.
EXPERIMENTAL PROCEDURES
Yeast Strains, Plasmids, and Growth Media
Yeast strain pp30 (MAT a, trp1-289, leu2-3, -112, his3-200, ura3-52, ade2-101,
lys2-801, hsc82KANMX4, hsp82KANMX4) was used in this study (Panaretou
et al., 1998). Plasmids were constructed as described previously (Mollapour
et al., 2011). yMps1 was C-terminally Myc tagged using primers listed in Table
S3 and pFA6a-13Myc-His3MX6 plasmid as the template. The EUROSCARF
collection of haploid non-essential kinase deletions in BY4741 (MAT a; Dhis3-
D1; leu2-D0; met15-D0; ura3-D0) background (http://www.euroscarf.de/
search.php?name=Order) was used to screen for T101 phosphorylation (Table
S1). The yeast essential kinases libraryunder the control ofGAL1-promoterwas
obtained from Dharmacon (http://dharmacon.gelifesciences.com/). Detailed
procedures, a list of primers (Table S3), and media conditions for both yeast
and mammalian cells are provided in the Supplemental Information.882 Cell Reports 14, 872–884, February 2, 2016 ª2016 The AuthorsProtein Extraction, Isolation, PreScission Protease Cleavage, and
Immunoblotting
Preparation and analysis of total protein lysate by western blot was described
previously (Mollapour et al., 2010). A detailed method for protein precipita-
tions, cleavage by PreScission protease, and detection by western blotting
and assays for Hsp90 client binding and activity for both yeast andmammalian
systems are presented in the Supplemental Information.
Interactome Analysis of Phosphorylation of T101-yHsp90 by Mass
Spectrometry
Yeast cells expressing T101A-yHsp90-His6 (T101A) or T101E-yHsp90-His6
(T101E) as the sole yHsp90 protein were grown to mid-log phase. T101A
and T101E interactomes were purified using Ni-NTA agarose, separated by
SDS-PAGE, and subjected to proteomic analysis. Briefly, gel slices were sub-
jected to in-gel proteolysis; tryptic peptides were purified, differentially labeled
by carboxyl-terminal 18O exchange, and analyzed via LC-MS/MS as described
in the Supplemental Information.
In Vitro Kinase Assay
Yeast Hsp90 and the mutant T101A were N-terminally His6-tagged using the
pRSETA plasmid. They were then expressed in bacteria, and 2 mg of protein
extracts were incubated with 50 ml of Ni-NTA agarose. yMps1-Myc and
Cdc14-GST were expressed and purified from yeast. These proteins were
also salt-stripped with 0.5 M NaCl prior to addition to the in vitro reaction as
previously described (Mollapour et al., 2010).
Flow Cytometric Analysis
Flow cytometric analysis was performed as described previously (Mollapour
et al., 2010). A detailed procedure is found in the Supplemental Information.
Isothermal Titration Calorimetry and Kd Determinations
Isothermal titration calorimetry (ITC) and diffusion constant (Kd) determinations
were performed as described previously (Prodromou et al., 2000). Additional
information can be found in the Supplemental Information.
Hsp90 ATPase Activity In Vivo
Yeast Hsp90-His6 and the T101A and T101E mutants were isolated, and their
ATPase activity was measured as previously described (Kamal et al., 2003),
with exceptions detailed in the Supplemental Information.
Ex Vivo Culture and Analysis of Human RCC Tumors
Tumor tissues of the patients with conventional RCC were obtained with
written informed consent from the Department of Urology at SUNY (State Uni-
versity of New York) Upstate Medical University. Patients had no history of
hereditary Von Hippel-Lindau (VHL) disease.
At the time of radical or partial nephrectomy, which was done with <15 min
of renal ischemia, RCC tumors were dissected into 3- to 5-mm3 pieces and
cultured on a presoaked gelatin sponge (Johnson & Johnson) in 24-well plates
containing 2 ml RPMI-1640 with 10% FBS, antibiotic/antimycotic solution,
with or without 10 mMNMS-P715. Tissues were cultured at 37C for 24 hr, fol-
lowed by the addition of 100 nM fluorescently labeled GB (STA-12-9455; FL-
GB) and further incubation at 37C for 6 hr.
Using an ex vivo method as previously described (Kedar et al., 1982),
approximately 107 cells were isolated from the RCC solid tumor analysis by
flow cytometry and western blot.
Statistical Analysis
Data were analyzed with Student’s t test. Asterisks in figures indicate signifi-
cant differences (p < 0.05). Error bars represent the SD for three independent
experiments.
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